Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
BNF presentation directory
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
- Chemical substance: Ranolazine
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Ranolazine 375mg modified-release tablets
0206030Z0AAAAAA
|
Ranolazine | Ranolazine | Cardiovascular System | 101,966 |
|
Ranolazine 500mg modified-release tablets
0206030Z0AAABAB
|
Ranolazine | Ranolazine | Cardiovascular System | 72,396 |
|
Ranolazine 750mg modified-release tablets
0206030Z0AAACAC
|
Ranolazine | Ranolazine | Cardiovascular System | 41,880 |
|
Ranexa 375mg modified-release tablets
0206030Z0BBAAAA
|
Ranexa | Ranolazine | Cardiovascular System | 1,758 |
|
Ranexa 500mg modified-release tablets
0206030Z0BBABAB
|
Ranexa | Ranolazine | Cardiovascular System | 1,034 |
|
Ranexa 750mg modified-release tablets
0206030Z0BBACAC
|
Ranexa | Ranolazine | Cardiovascular System | 451 |
|
Ranogelan 375mg prolonged-release tablets
0206030Z0BDAAAA
|
Ranogelan | Ranolazine | Cardiovascular System | 21 |
|
Ranogelan 500mg prolonged-release tablets
0206030Z0BDABAB
|
Ranogelan | Ranolazine | Cardiovascular System | 8 |
|
Ranogelan 750mg prolonged-release tablets
0206030Z0BDACAC
|
Ranogelan | Ranolazine | Cardiovascular System | 8 |
|
Anzipro 375mg modified-release tablets
0206030Z0BCAAAA
|
Anzipro | Ranolazine | Cardiovascular System | 2 |
|
Anzipro 500mg modified-release tablets
0206030Z0BCABAB
|
Anzipro | Ranolazine | Cardiovascular System | 2 |
|
Anzipro 750mg modified-release tablets
0206030Z0BCACAC
|
Anzipro | Ranolazine | Cardiovascular System | 1 |
Why monitor BNF codes?
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Understand demand drivers
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.